The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
 
David Planchard
Honoraria - PeerVoice; Prime Oncology
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MedImmune; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst)
 
Byoung Chul Cho
Stock and Other Ownership Interests - Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Jhanelle Elaine Gray
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Genentech/Roche; Janssen; Lilly
Speakers' Bureau - Genentech
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Epic Sciences (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Janssen Oncology
 
Luis G. Paz-Ares
Leadership - European Medicines Agency (I); Genomica
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sysmex
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca Spain; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Mustafa Ozguroglu
No Relationships to Disclose
 
Augusto E. Villegas
Speakers' Bureau - AstraZeneca
 
Davey B. Daniel
Research Funding - Abbvie (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Guardant Health (Inst); Immunomedics (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Merus NV (Inst); Novartis (Inst); Novartis (Inst)
 
David Vicente
No Relationships to Disclose
 
Shuji Murakami
No Relationships to Disclose
 
Rina Hui
Honoraria - Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Roche
 
Takayasu Kurata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); MSD Oncology (Inst)
 
Alberto Chiappori
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; genentech; Novartis; PharmaMar
Speakers' Bureau - Boehringer Ingelheim; Celgene; Genentech; Merck; Takeda
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis
 
Ki Hyeong Lee
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD
 
Maike De Wit
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Yu Gu
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca
 
Catherine Wadsworth
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Phillip A. Dennis
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Scott Joseph Antonia
Stock and Other Ownership Interests - Cellular Biomedicine Group
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cellular Biomedicine Group; Memgen; Merck; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; FLX Bio; Memgen; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; FLX Bio; Merck; Novartis